Design Therapeutics, Inc. (DSGN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Design Therapeutics, Inc. (DSGN) closed at USD 9.73 on 2026-10-14, a change of +45.7 % over the past year, with a market capitalization of USD 655.86M.

Design Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Design Therapeutics, Inc. key figures

Previous close

USD 9.73 (2026-10-14)

1-year change

+45.7 %

Market cap

USD 655.86M

Enterprise value

USD 451.12M

P/E ratio (trailing)

-8.25

P/E ratio (forward)

-6.47

EPS (trailing)

-1.27

EPS (forward)

-1.62

PEG ratio

n/a

Price to book

3.25

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.67

Employees

55

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Design Therapeutics, Inc. and compare it with other stocks.